RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NS CLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NS CLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NS CLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab. © 2013 Landes Bioscience.

Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab / Nicholas G., Zaorsky; Yunguang, Sun; Zixuan, Wang; Joshua, Palmer; Fortina, Paolo; Charalambos, Solomides; Maria Werner, Wasik; Adam P., Dicker; Rita, Axelrod; Barbara, Campling; Nathaniel, Evans; Scott, Cowan; Bo, Lu. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - 14:10(2013), pp. 883-887. [10.4161/cbt.25942]

Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab

FORTINA, PAOLO;
2013

Abstract

RTOG 0839 is a Phase II study of pre-operative chemoradiotherapy with or without panitumumab in potentially operable locally advanced non-small cell lung cancer (NS CLC). The investigational agent, panitumumab, is an anti-epithelial growth factor receptor (EGFR) antibody that improves progression-free survival in chemorefractory metastatic colorectal cancer (mCRC). Recently, both KRAS mutational status (i.e., mutated or not) and subtype (i.e., activating or inactivating) have been shown to be predictive of response to anti-EGFR therapy in mCRC. However, in NS CLC, it is unknown if KRAS mutational status or subtype predict benefit to anti-EGFR therapies because of unique genetic and epigenetic factors unique to each cancer. We present a patient with stage III NS CLC containing a KRAS G12D activating mutation who had a partial pathologic response, with disappearance of a minor KRAS mutant clone. This case suggests possible eradication of the G12D KRAS lung cancer clones by concurrent chemoradiation with panitumumab. © 2013 Landes Bioscience.
2013
01 Pubblicazione su rivista::01a Articolo in rivista
Identification of a KRAS mutation in a patient with non-small cell lung cancer treated with chemoradiotherapy and panitumumab / Nicholas G., Zaorsky; Yunguang, Sun; Zixuan, Wang; Joshua, Palmer; Fortina, Paolo; Charalambos, Solomides; Maria Werner, Wasik; Adam P., Dicker; Rita, Axelrod; Barbara, Campling; Nathaniel, Evans; Scott, Cowan; Bo, Lu. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - 14:10(2013), pp. 883-887. [10.4161/cbt.25942]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/556793
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 5
social impact